ProBiotix Health launches Blood Pressure reducing supplement CholBiome®BP
A global leader in microbiome modulating compounds for use in functional foods and supplements, ProBiotix Health (‘ProBiotix’), an OptiBiotix Health PLC (‘OptiBiotix’) subsidiary company, has announced the launch of an innovative tri-layer tablet, CholBiome®BP. It combines four science-backed, natural ingredients to aid hypertension and cardiovascular health.
According to research from the World Health Organisation (‘WHO’), it is estimated that 1.13 billion people worldwide have hypertension, with two thirds of those affected living in low- and middle-income countries. In addition, one in four men and one in five women have experienced hypertension, and fewer than one in five individuals with hypertension have been able to keep it under control. Due to this, the disease is a major cause of premature death.
To help tackle the global health issue, the latest advancements in science and technology from ProBiotix uses a multi-targeted mechanism approach to improve consumer cardiovascular health. CholBiomeBP utilises specialised tri-layer tablet technology to combine four synergistic ingredients – that have previously been incompatible – and slowly releases them into the human body. This multi-tiered approach increases the supplement’s stability and survivability throughout the digestive system, alongside boosting its effectiveness.
Mikkel Hvid-Hansen, Commercial Director at ProBiotix, said: “We are thrilled to launch CholBiomeBP as part of the CholBiome brand portfolio. As health and wellness becomes front of mind for many, CholBiomeBP is a natural food supplement containing our patented probiotic strain LPLDL®, Thiamine (Vitamin B1), which contributes to the normal function of the heart, the semi-essential amino acid L-Arginine and the micronutrient CoEnzyme Q10. By combining all four ingredients together in a unique way, CholBiomeBP helps to support normal cardiac function, as recognised by EFSA.”
In an independent, 12-week clinical study featuring 40 adults with high blood pressure, CholBiomeBP demonstrated its efficacy with a statistically significant decrease in diastolic blood pressure and a reduction in systolic blood pressure. In addition, the supplement also resulted in a drop in ‘bad’ LDL cholesterol and a decrease in total cholesterol. This means the GMO and allergen free product is an effective way to aid hypertension in adults and improve overall cardiovascular health.
Steven Riley, Director of Marketing and Consumer Sales at OptiBiotix, said: “We’re pleased to announce that CholBiomeBP will be joining the OptiBiotix Online store and will be complementing our growing science-backed cardiovascular health range. The blood pressure reducing supplement is a key part of our commercial growth and is an exciting step forward to support consumers on their journey towards a healthier lifestyle.
“As a global company with headquarters in the UK, we want to raise awareness of how important it is for consumers to get their blood pressure checked. We encourage those who are worried about their blood pressure to measure it at home with an accurate reader as per guidance from the British Heart Foundation.”
CholBiome®BP will be available for purchase in the OptiBiotix Online store this September. For more information on the CholBiome® range, please visit https://optibiotix.online/collections/cholbiome-range.